Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
40 hedge funds and large institutions have $25.6M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 14 closing their positions.
55% more call options, than puts
Call options by funds: $812K | Put options by funds: $525K
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
13% less funds holding
Funds holding: 46 → 40 (-6)
13% less capital invested
Capital invested by funds: $29.4M → $25.6M (-$3.84M)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$741K |
| 2 |
ACM
Altium Capital Management
New York
|
+$690K |
| 3 |
VCWA
Vanguard Capital Wealth Advisors
Denver,
Colorado
|
+$482K |
| 4 |
BlackRock
New York
|
+$463K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$378K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.63M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$968K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$731K |
| 4 |
Renaissance Technologies
New York
|
-$326K |
| 5 |
E
Ergoteles
New York
|
-$243K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| – | -$23K | -291 | Closed |
|
52
Jane Street
New York
| – | -$21K | -265 | Closed |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| – | -$21K | -265 | Closed |
|
54
JP Morgan Chase
New York
| – | -$1.97K | -32 | -97% |
|
ELOX Hedge Fund Activity: Q3 2021 in Review
40 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q3 2021, worth a combined $25.6M — down 13% from $29.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ELOX and 8 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 12 added.
The largest buyer was Two Sigma Advisers, adding an estimated $741K. The largest seller was Nantahala Capital Management, cutting an estimated $1.63M.
- 40 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q3 2021, down from 46 in Q2 2021.
- Funds reported $25.6M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q3 2021, down 13% quarter-over-quarter.
- 8 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 14 closed out, a net change of -6 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Two Sigma Advisers, an estimated $741K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was Nantahala Capital Management, an estimated $1.63M sold.
Based on aggregated 13F filings for Q3 2021.